Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and aprepitant

erlotinib hydrochloride has been researched along with aprepitant in 6 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(aprepitant)		Trials
(aprepitant)		Recent Studies (post-2010) (aprepitant)
4,3537863,033769229521

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)aprepitant (IC50)
Cytochrome P450 3A4Homo sapiens (human)0.046
Substance-P receptorHomo sapiens (human)0.0002
Substance-P receptorMeriones unguiculatus (Mongolian gerbil)0.0001

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Santini, D; Tonini, G; Vincenzi, B1
Levêque, D1
Blanchet, B; Goldwasser, F; Mir, O1
Buhren, BA; Gerber, PA; Homey, B1
Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB2

Other Studies

6 other study(ies) available for erlotinib hydrochloride and aprepitant

ArticleYear
Aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2010, Jul-22, Volume: 363, Issue:4

    Topics: Adult; Aged; Aprepitant; Erlotinib Hydrochloride; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Kinase Inhibitors; Pruritus; Quinazolines

2010
Aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2010, 10-21, Volume: 363, Issue:17

    Topics: Antineoplastic Agents; Aprepitant; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines

2010
More on aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines

2011
More on aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P

2011
EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
    Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:1

    Topics: Animals; Aprepitant; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Ventricular Function, Left

2015
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.
    Molecular and cellular biochemistry, 2020, Volume: 465, Issue:1-2

    Topics: Animals; Aprepitant; Drug Eruptions; Erlotinib Hydrochloride; Male; Nervous System Diseases; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley

2020